Literature DB >> 33595832

Gender differences in progressive supranuclear palsy.

Rohan R Mahale1, Syam Krishnan2, K P Divya2, V T Jisha3, Asha Kishore4.   

Abstract

The gender differences in progressive supranuclear palsy (PSP) are not extensively studied. The objective of this study was to determine the gender differences in the phenotypic expression and progression in PSP. We did a retrospective review of medical records of patients diagnosed with PSP over a 21-year period. The interval between disease onset and attainment of the five clinical disability milestones namely wheel chair dependency, unintelligible speech, severe dysphagia, severe cognitive impairment and urinary catheterization was used to determine the progression. Data was analysed from the case records of 334 patients with PSP. 209 patients (62.2%) were male and 125 (37.4%) among the patients were women (male:female ratio = 1.6:1). Males had older age at onset with longer duration of illness at time of presentation. Tremors were more common, PSP-P phenotype was more frequent and time to attain wheelchair dependency was earlier in males. Falls within 1 year of disease onset, apathy and executive dysfunction were more frequent and time to attain unintelligible speech, severe dysphagia and cognitive impairment were earlier in females. This study in a large cohort of clinically diagnosed cases of PSP has showed that gender differences exist in PSP in terms of clinical characteristics, progression of the disease.
© 2021. Belgian Neurological Society.

Entities:  

Keywords:  Gender; Prognosis; Progressive supranuclear palsy

Mesh:

Year:  2021        PMID: 33595832     DOI: 10.1007/s13760-021-01599-0

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  1 in total

1.  Normative Data for Brainstem Structures, the Midbrain-to-Pons Ratio, and the Magnetic Resonance Parkinsonism Index.

Authors:  S T Ruiz; R V Bakklund; A K Håberg; E M Berntsen
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-07       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.